Immune checkpoint inhibitors (ICIs) continue to break ground in a multitude of cancer types. With ever-evolving data and recommendations, oncology clinicians must keep pace with the latest ICI updates.

This recorded CME-certified session tackles questions surrounding topics related to immune checkpoint inhibitors with discussion on:

• Role of biomarkers with ICI selection and monitoring
• Latest expanded ICI indications
• Immune-related adverse events

This session also features Q&A from the meeting highlighting common questions related to immunooncology (IO) treatments.

Updates: 

On July 26, 2021, the FDA approved pembrolizumab for high-risk, early-stage, TNBC in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery.

On August 10, 2021, the FDA approved combination lenvatinib plus pembrolizumab for first-line treatment of adult patients with advanced renal cell carcinoma.

On August 18, 2021, the FDA granted accelerated approval to dostarlimab-gxly for dMMR recurrent or advanced solid tumors that have progressed on or following prior treatment and who have no satisfactory alternative treatment options

On August 20, 2021, the FDA approved adjuvant nivolumab in patients with urothelial carcinoma who are at a high risk of recurrence following radical resection regardless of previous treatment with neoadjuvant chemotherapy, nodal involvement, or PD-L1 status.

On October 13, 2021, the FDA approved pembrolizumab in combination with chemotherapy, with or without bevacizumab, for patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1.

On October 15, 2021, the FDA approved atezolizumab as adjuvant treatment following resection and platinum-based chemotherapy in patients with stage II to IIIA NSCLC whose tumors have PD-L1 expression on ≥1% or greater of tumor cells.

On November 17, 2021: The FDA has approved pembrolizumab for the adjuvant treatment of patients with renal cell carcinoma at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.

On January 26, 2022, the FDA approved the T cell receptor therapeutic, tebentafusp-tebn for unresectable or metastatic unveal melanoma.

On February 28, 2022: Ciltacabtagene autoleucel is now approved for patients with relapsed or refractory multiple myeloma.

Update March 4, 2022: nivolumab with platinum-doublet chemotherapy is now approved for adult patients with resectable NSCLC in the neoadjuvant setting.

Update March 18, 2022: The FDA has approved the fixed-dose combination of relatlimab plus nivolumab for the treatment of adult and pediatric patients greater than or equal to 12 years old with unresectable or metastatic melanoma.

Update May 27, 2022: The FDA has approved nivolumab in combination with fluoropyrimidine- and platinum-containing chemotherapy and nivolumab plus ipilimumab as a first-line treatment for adult patients with unresevtable advanced or metastatic esopageal squamous cell carcinoma regardless of PD-L1 status.

1. Active Internet connection (DSL or Cable). Dial-up connection will have constant buffering problem.
2. Compatible with Windows PC and MAC (256 MB of RAM or higher)
3. Activity is best viewed on Internet Explorer 9.0 or higher, Safari 5.0 or higher and Firefox 29.0 or higher
4. Adobe Flash Player 12.0 (or higher). Click here to download Adobe Flash Player for free.
5. Adobe Reader to print certificate. Click here to download Adobe Reader for free.
6. Allow ActiveX controls to run on your computer: If the yellow strip appears on the top of your web browser while running the Webcast, right click on it and select Allow blocked contents to run.

Turn the Pop-up blocker off: On the Tools menu, point to Pop-up Blocker, and then click Turn Off Pop-up Blocker